Morgan Stanley raised the firm’s price target on Doximity (DOCS) to $62 from $60 and keeps an Equal Weight rating on the shares. Doximity beat and raised despite macro cross-currents, notes the analyst, who sees momentum in the business and a strong balance sheet “allowing Doximity to go on offense in completing a strategic technology tuck-in.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $75 from $65 at Raymond James
- Doximity price target raised to $65 from $62 at Wells Fargo
- Doximity price target raised to $59 from $50 at Canaccord
- Doximity’s Strong Q1 and AI Innovations Drive Buy Rating Despite Growth Concerns
- Doximity Reports Strong Q1 Earnings with Revenue Growth